TY - JOUR
T1 - Classification criteria for the Antiphospholipid Syndrome
T2 - Not the same as diagnostic criteria for Antiphospholipid Syndrome
AU - Favaloro, Emmanuel J
AU - Pasalic, Leonardo
AU - Lippi, Giuseppe
PY - 2024
Y1 - 2024
N2 - The latest consensus “guidelines” outlining revised Classification Criteria for antiphospholipid syndrome (APS) has just been published.1 The aim of this publication was to develop new APS classification criteria with high specificity to be used in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR). Currently, classification of APS, for identification of homogeneous research cohorts, is based on the Sapporo criteria published in 1999,2 as revised in Sydney in 2006.3 The Sydney revised Sapporo criteria for APS require clinical features (thrombosis or pregnancy morbidity) and laboratory tests for antiphospholipid antibodies (aPL; i.e., lupus anticoagulant [LA],IgG/IgM anticardiolipin antibodies [aCL], and/or IgG/IgManti-b2-glycoprotein I antibodies [aβ2GPI]), with a minimum of one positive aPL test, performed on two occasions at least12-week apart.3
AB - The latest consensus “guidelines” outlining revised Classification Criteria for antiphospholipid syndrome (APS) has just been published.1 The aim of this publication was to develop new APS classification criteria with high specificity to be used in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR). Currently, classification of APS, for identification of homogeneous research cohorts, is based on the Sapporo criteria published in 1999,2 as revised in Sydney in 2006.3 The Sydney revised Sapporo criteria for APS require clinical features (thrombosis or pregnancy morbidity) and laboratory tests for antiphospholipid antibodies (aPL; i.e., lupus anticoagulant [LA],IgG/IgM anticardiolipin antibodies [aCL], and/or IgG/IgManti-b2-glycoprotein I antibodies [aβ2GPI]), with a minimum of one positive aPL test, performed on two occasions at least12-week apart.3
UR - http://www.scopus.com/inward/record.url?scp=85175874787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175874787&partnerID=8YFLogxK
U2 - 10.1055/s-0043-1776318
DO - 10.1055/s-0043-1776318
M3 - Article
C2 - 37863041
SN - 0094-6176
VL - 50
SP - 605
EP - 608
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
IS - 4
ER -